@article{ref1,
title="The effect of an abuse-deterrent opioid formulation on opioid abuse-related outcomes in the post-marketing setting",
journal="Clinical pharmacology and therapeutics",
year="2016",
author="Coplan, Paul M. and Chilcoat, Howard D. and Butler, Stephen F. and Sellers, Edward M. and Kadakia, Aditi and Harikrishnan, Venkatesh and Haddox, J. David and Dart, Richard C.",
volume="100",
number="3",
pages="275-286",
abstract="An extended-release opioid analgesic (OxyContin, abbreviated as OC) was reformulated with abuse-deterrent properties to deter abuse. This report examines changes in abuse through oral and non-oral routes, doctor-shopping, and fatalities in ten studies 3.5 years after reformulation. Changes in OC abuse from one year before to three years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor-shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse-deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for non-oral than oral abuse. Abuse-deterrent opioids may mitigate abuse and overdose risks among chronic pain patients. This article is protected by copyright. All rights reserved.<br><br>© 2016 American Society for Clinical Pharmacology and Therapeutics.<p /> <p>Language: en</p>",
language="en",
issn="0009-9236",
doi="10.1002/cpt.390",
url="http://dx.doi.org/10.1002/cpt.390"
}